Work

Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease

Year: 2025

Type: article

Abstract: Recently, two proposals for defining Parkinson's disease and its related pathogenic processes have been published. In this viewpoint, we discuss the primary drivers behind these efforts, the future directions, and the challenges that must be addressed. While finding biomarkers is a mandatory step for better precision medicine and optimal patient stratification in therapeutic trials, we argue that a biological definition of Parkinson's disease based on a single biomarker will struggle to account for the complexity of the mechanisms involved in developing the disease. Additionally, a biological definition of asymptomatic patients should rely on a thorough understanding of patients' clinical trajectories, which is currently not the case in synucleinopathies.

Source: Journal of Parkinson s Disease

DOI: 10.1177/1877718x241313443

Authors: David Bendetowicz, Vincent Planche, Erwan Bezard, Benjamin Dehay, Wassilios G Meissner

Institutions: Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Bordeaux, Institut des Maladies Neurodégénératives, New Zealand Brain Research Institute, University of Otago

Language: English

Topic: Parkinson's Disease Mechanisms and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: Institut National de la Santé et de la Recherche Médicale